SciELO - Scientific Electronic Library Online

 
vol.17 número1Range of movement, power and pinch grip strength post flexor tendon repairMultilevel paediatric idiopathic intervertebral disc calcification: a case study índice de autoresíndice de assuntospesquisa de artigos
Home Pagelista alfabética de periódicos  

Serviços Personalizados

Artigo

Indicadores

Links relacionados

  • Em processo de indexaçãoCitado por Google
  • Em processo de indexaçãoSimilares em Google

Compartilhar


SA Orthopaedic Journal

versão On-line ISSN 2309-8309
versão impressa ISSN 1681-150X

Resumo

RAUBENHEIMER, EJ et al. Recent advances in the pharmaceutical manipulation of bone remodelling: the quest for a healthy skeleton. SA orthop. j. [online]. 2018, vol.17, n.1, pp.55-60. ISSN 2309-8309.  http://dx.doi.org/10.17159/2309-8309/2018/v17n1a8.

INTRODUCTION: Biochemical characterisation of the autocrine, paracrine and endocrine mediators of bone remodelling provides a scientific basis for the development of pharmaceuticals and autoantibodies which could induce a desired skeletal phenotype. The manipulation of bone remodelling in patients at risk for skeletal disease is gaining clinical momentum due to the benefits of maintaining quality of life rather than restoring the long-term dire consequences of skeletal catabolism. METHODS: A narrative review of current literature pertaining to the modes of action of pharmaceuticals and autoantibodies which manipulate skeletal metabolism was performed. RESULTS: Pharmaceuticals and autoantibodies which manipulate skeletal remodelling can be broadly divided into three categories: bone resorption inhibitors, bone formation stimulators and bone resorption and formation modulators. The mechanisms of action of these medications are briefly summarised and reference is made to the relevant pharmaceuticals and autoantibodies available. Level of evidence: Level 5.

Palavras-chave : osteoporosis; skeletal health; osteoinductive medication; antiresorptive medication; bone remodelling.

        · texto em Inglês     · Inglês ( pdf )

 

Creative Commons License Todo o conteúdo deste periódico, exceto onde está identificado, está licenciado sob uma Licença Creative Commons